Preference of methadone maintenance patients for the integrative and decentralized service delivery models in Vietnam

Harm Reduction Journal

Carl A. Latkin⁴  Linh Khanh Nguyen²  Huong Thu Thi Phan¹  Long Hoang Nguyen³  Bach Xuan Tran⁴ 

[1] Authority of HIV/AIDS Control, Ministry of Health, Hanoi, Vietnam;Illinois Wesleyan University, Bloomington, USA;School of Medicine and Pharmacy, Vietnam National University, Hanoi, Vietnam;Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

关键词: Vietnam;    MMT;    Preference;    Decentralized;    Integrative;    Methadone;   

Others  :  1230095
DOI  :  10.1186/s12954-015-0063-0

 received in 2015-06-21, accepted in 2015-08-23,  发布年份 2015

【 摘 要 】

Background

Integrating and decentralizing services are essential to increase the accessibility and provide comprehensive care for methadone patients. Moreover, they assure the sustainability of a HIV/AIDS prevention program by reducing the implementation cost. This study aimed to measure the preference of patients enrolling in a MMT program for integrated and decentralized MMT clinics and then further examine related factors.

Methods

A cross-sectional study was conducted among 510 patients receiving methadone at 3 clinics in Hanoi. Structured questionnaires were used to collect data about the preference for integrated and decentralized MMT services. Covariates including socio-economic status; health-related quality of life (using EQ-5D-5 L instrument) and HIV status; history of drug use along with MMT treatment; and exposure to the discrimination within family and community were also investigated. Multivariate logistic regression with polynomial fractions was used to identify the determinants of preference for integrative and decentralized models.

Results

Of 510 patients enrolled, 66.7 and 60.8 % preferred integrated and decentralized models, respectively. The main reason for preferring the integrative model was the convenience of use of various services (53.2 %), while more privacy (43.5 %) was the primary reason to select stand-alone model. People preferred the decentralized model primarily because of travel cost reduction (95.0 %), while the main reason for not selecting the model was increased privacy (7.7 %). After adjusting for covariates, factors influencing the preference for integrative model were poor socioeconomic status, anxiety/depression, history of drug rehabilitation, and ever disclosed health status; while exposure to community discrimination inversely associated with this preference. In addition, people who were self-employed, had a longer duration of MMT, and use current MMT with comprehensive HIV services were less likely to select decentralized model.

Conclusion

In conclusion, the study confirmed the high preference of MMT patients for the integrative and decentralized MMT service delivery models. The convenience of healthcare services utilization and reduction of geographical barriers were the main reasons to use those models within drug use populations in Vietnam. Countering community stigma and encouraging communication between patients and their societies needed to be considered when implementing those models.

【 授权许可】

   
2015 Tran et al.

【 参考文献 】

• [1]The Commission on AIDS in Asia. Redefining AIDS in Asia: Crafting an effective response. Oxford University Press 258 pages Available at http://data.unaids.org/pub/Report/2008/20080326_report_commission_aids_en.pdf Accessed November 1, 2012. 2008.
• [2]Wolfe D, Carrieri MP, Shepard D. Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet. 2010; 376(9738):355-66.
• [3]Bobrova N, Sarang A, Stuikyte R, Lezhentsev K. Obstacles in provision of anti-retroviral treatment to drug users in Central and Eastern Europe and Central Asia: a regional overview. The International journal on drug policy. 2007; 18(4):313-8.
• [4]Cambiano V, Lampe FC, Rodger AJ, Smith CJ, Geretti AM, Lodwick RK et al.. Long-term trends in adherence to antiretroviral therapy from start of HAART. Aids. 2010; 24(8):1153-62.
• [5]Organization WH. Policy and programming guide for HIV/AIDS prevention and care among injecting drug users. Switzerland, Geneva; 2005.
• [6]Ward J, Mattick RP, Hall W. The effectiveness of methadone maintenance treatment: an overview. Drug and alcohol review. 1994; 13(3):327-35.
• [7]World Health Organization. Proposal for the inclusion of Methadone in the WHO model list of essential medicines. Geneva, Switzerland. 2004.
• [8]Nguyen TT, Nguyen LT, Pham MD, Vu HH, Mulvey KP. Methadone maintenance therapy in Vietnam: an overview and scaling-up plan. Advances in preventive medicine. 2012; 2012:732484.
• [9]Masson CL, Barnett PG, Sees KL, Delucchi KL, Rosen A, Wong W et al.. Cost and cost-effectiveness of standard methadone maintenance treatment compared to enriched 180-day methadone detoxification. Addiction. 2004; 99(6):718-26.
• [10]Tran BX, Ohinmaa A, Duong AT, Nguyen LT, Vu PX, Mills S et al.. The cost-effectiveness and budget impact of Vietnam’s methadone maintenance treatment programme in HIV prevention and treatment among injection drug users. Global public health. 2012; 7(10):1080-94.
• [11]Tran BX, Ohinmaa A, Duong AT, Do NT, Nguyen LT, Mills S et al.. Cost-effectiveness of methadone maintenance treatment for HIV-positive drug users in Vietnam. AIDS care. 2012; 24(3):283-90.
• [12]Organization WH. Technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users, 2012 revision. World Health Organization, Geneva, Switzerland; 2012.
• [13]Tran BX, Ohinmaa A, Nguyen LT, Nguyen TA, Nguyen TH. Determinants of health-related quality of life in adults living with HIV in Vietnam. AIDS Care. 2011; 23(10):1236-45.
• [14]Tran BX. Quality of life outcomes of antiretroviral treatment for HIV/AIDS patients in Vietnam. PloS one. 2012; 7(7):e41062.
• [15]Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA et al.. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet. 2008; 372(9651):1733-45.
• [16]El-Bassel N, Shaw SA, Dasgupta A, Strathdee SA. Drug use as a driver of HIV risks: re-emerging and emerging issues. Current opinion in HIV and AIDS. 2014; 9(2):150-5.
• [17]van Beek I. Case study: accessible primary health care—a foundation to improve health outcomes for people who inject drugs. The International journal on drug policy. 2007; 18(4):329-32.
• [18]O'Connor PG, Molde S, Henry S, Shockcor WT, Schottenfeld RS. Human immunodeficiency virus infection in intravenous drug users: a model for primary care. The American journal of medicine. 1992; 93(4):382-6.
• [19]Selwyn PA, Budner NS, Wasserman WC, Arno PS. Utilization of on-site primary care services by HIV-seropositive and seronegative drug users in a methadone maintenance program. Public Health Reports. 1993; 108(4):492-500.
• [20]Umbricht-Schneiter A, Ginn DH, Pabst KM, Bigelow GE. Providing medical care to methadone clinic patients: referral vs on-site care. American Journal of Public Health. 1994; 84(2):207-10.
• [21]Tran BX. Willingness to pay for methadone maintenance treatment in Vietnamese epicentres of injection-drug-driven HIV infection. Bulletin of the World Health Organization. 2013; 91(7):475-82.
• [22]Dijkgraaf MG, van der Zanden BP, de Borgie CA, Blanken P, van Ree JM, van den Brink W. Cost utility analysis of co-prescribed heroin compared with methadone maintenance treatment in heroin addicts in two randomised trials. Bmj. 2005; 330(7503):1297.
• [23]Vanagas G, Padaiga Z, Bagdonas E. Cost-utility analysis of methadone maintenance treatment: a methodological approach. Substance use & misuse. 2006; 41(1):87-101.
• [24]Afriandi I, Siregar AY, Meheus F, Hidayat T, van der Ven A, van Crevel R et al.. Costs of hospital-based methadone maintenance treatment in HIV/AIDS control among injecting drug users in Indonesia. Health Policy. 2010; 95(1):69-73.
• [25]Tran BX, Ohinmaa A, Duong AT, Nguyen LT, Vu PX, Mills S, Houston S, Jacobs P. The cost-effectiveness and budget impact of Vietnam’s methadone maintenance treatment programme in HIV prevention and treatment among injection drug users. Global public health. 2012; 7(10):1080-94.
• [26]Kim JY, Farmer P, Porter ME. Redefining global health-care delivery. Lancet. 2013; 382(9897):1060-9.
• [27]Decision 1001/QD-TTg on National Strategy on Drug Control, (2011).
• [28]Decision 108/ND-CP detailing the law on HIV/AIDS, (2007).
• [29]Guideline on the Implementation of HIV/AIDS Law, (2007).
• [30]Decision 3140/QD-BYT, dated 30/08/2010, of the Ministry of Health to issue guidelines on substitution treatment by methadone and implementation instructions, (2010).
• [31]Vietnam Authority of HIV/AIDS Control. Update the implementation of opioid substance abuse treatment by Methadone (Vietnamese). Ministry of Health, Hanoi, Vietnam. 2015.
• [32]The annual review of HIV/AIDS control and prevention in the first six months 2015 and action plan in the last six months in 2015. Hanoi, Ministry of Health; 2014.
• [33]Proposal: innovations in implementing illicit drug detoxification in Vietnam up to 2020. Hanoi, Vietnam; 2013.
• [34]Tran BX, Nguyen LT. Impact of methadone maintenance on health utility, health care utilization and expenditure in drug users with HIV/AIDS. The International journal on drug policy. 2013; 24(6):e105-10.
• [35]Tran BX, Duong AT, Nguyen LT, Hwang J, Nguyen BT, Nguyen QT et al.. Financial burden of health care for HIV/AIDS patients in Vietnam. Trop Med Int Health. 2013; 18(2):212-8.
• [36]Drainoni ML, Farrell C, Sorensen-Alawad A, Palmisano JN, Chaisson C, Walley AY. Patient perspectives of an integrated program of medical care and substance use treatment. AIDS patient care and STDs. 2014; 28(2):71-81.
• [37]Mulamba D, Fullem A, Hirschhorn L, Allers C, Oser R, Rau B. Decentralizing antiretroviral treatment services at primary health care facilities: a guide to expanding access in resource-limited, generalized hiv epidemic settings Arlington. VA, USAIDS; 2010.
• [38]Group E. EQ-5D-5L User Guide: Basic information on how to use the EQ-5D-5L instrument. Rotterdam, The Netherlands. 2011. http://www.euroqol.org/fileadmin/user_upload/Documenten/PDF/Folders_Flyers/EQ-5D-5L_UserGuide_2015.pdf. Accessed 1–9 2013.
• [39]Organization WH. Treatment of injecting drug users with HIV/AIDS: promoting access and optimizing service delivery. Switzerland, Geneva; 2006.
• [40]Samet JH, Stein MD, O'Connor PG. Models of medical care for HIV-infected drug users. Substance Abuse. 1995; 16(3):131-9.
• [41]Herman M, Gourevitch MN. Integrating primary care and methadone maintenance treatment: implementation issues. Journal of addictive diseases. 1997; 16(1):91-102.
• [42]Brienza RS, Stein MD, Chen M, Gogineni A, Sobota M, Maksad J et al.. Depression among needle exchange program and methadone maintenance clients. Journal of substance abuse treatment. 2000; 18(4):331-7.
• [43]Steward WT, Chandy S, Singh G, Panicker ST, Osmand TA, Heylen E et al.. Depression is not an inevitable outcome of disclosure avoidance: HIV stigma and mental health in a cohort of HIV-infected individuals from Southern India. Psychology, health & medicine. 2011; 16(1):74-85.
• [44]Lovejoy TI, Heckman TG. Depression moderates treatment efficacy of an HIV secondary-prevention intervention for HIV-positive late middle-age and older adults. Behav Med. 2014; 40(3):124-33.
• [45]Tran BX, Ohinmaa A, Duong AT, Do NT, Nguyen LT, Nguyen QC et al.. Changes in drug use are associated with health-related quality of life improvements among methadone maintenance patients with HIV/AIDS. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. 2012; 21(4):613-23.
• [46]Hammett TM, Wu Z, Duc TT, Stephens D, Sullivan S, Liu W et al.. ‘Social evils’ and harm reduction: the evolving policy environment for human immunodeficiency virus prevention among injection drug users in China and Vietnam. Addiction. 2008; 103(1):137-45.
• [47]Clarke S, Delamere S, McCullough L, Hopkins S, Bergin C, Mulcahy F. Assessing limiting factors to the acceptance of antiretroviral therapy in a large cohort of injecting drug users. HIV medicine. 2003; 4(1):33-7.
• [48]Friedmann PD, Alexander JA, Jin L, D'Aunno TA. On-site primary care and mental health services in outpatient drug abuse treatment units. The journal of behavioral health services & research. 1999; 26(1):80-94.
• [49]Samet JH, Friedmann P, Saitz R. Benefits of linking primary medical care and substance abuse services: patient, provider, and societal perspectives. Archives of internal medicine. 2001; 161(1):85-91.
• [50]Mukora R, Charalambous S, Dahab M, Hamilton R, Karstaedt A. A study of patient attitudes towards decentralisation of HIV care in an urban clinic in South Africa. BMC health services research. 2011; 11:205. BioMed Central Full Text
• [51]Hong KT, Anh NTV, Ogden J. “Because this is the disease of the century”: understanding HIV and AIDS-related stigma and discrimination in Vietnam. International Center for Research on Women, Washington D.C; 2004.
• [52]Nguyen P, Bich Hanh D, Lavergne MR, Mai T, Nguyen Q, Phillips JF et al.. The effect of a poverty reduction policy and service quality standards on commune-level primary health care utilization in Thai Nguyen Province, Vietnam. Health policy and planning. 2010; 25(4):262-71.
• [53]Saitz R, Mulvey KP, Plough A, Samet JH. Physician unawareness of serious substance abuse. The American journal of drug and alcohol abuse. 1997; 23(3):343-54.
• [54]Govindasamy D, Ford N, Kranzer K. Risk factors, barriers and facilitators for linkage to antiretroviral therapy care: a systematic review. Aids. 2012; 26(16):2059-67.
• [55]Suthar AB, Rutherford GW, Horvath T, Doherty MC, Negussie EK. Improving antiretroviral therapy scale-up and effectiveness through service integration and decentralization. Aids. 2014; 28 Suppl 2:S175-85.
• [56]Church K, Wringe A, Fakudze P, Kikuvi J, Simelane D, Mayhew SH. Are integrated HIV services less stigmatizing than stand-alone models of care? A comparative case study from Swaziland. Journal of the International AIDS Society. 2013; 16:17981.
• [57]Suri A, Gan K, Carpenter S. Voices from the field: perspectives from community health workers on health care delivery in rural KwaZulu-Natal, South Africa. The Journal of infectious diseases. 2007; 196 Suppl 3:S505-11.